- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00823004
Antagonist/Letrozole in Poor Responders
GnRH Antagonist /Letrozole Versus Microdose GnRH Agonist Flare Protocol in Poor Responders Undergoing in Vitro Fertilization
Failure to respond to controlled ovarian hyperstimulation (COH) is still a major concern in assisted reproduction and there is no consensus on the ovarian stimulation choice regime for poor responders.
Aim: To evaluate and compare the efficacy of a microdose GnRH agonist flare (MF) and a GnRH antagonist/letrozole (A/L) protocols in poor responders undergoing in vitro fertilization (IVF).
Methods: One hundred eighty poor responder patients will be randomized to an ovarian stimulation protocol with either a MF or a letrozole and high dose FSH/hMG and flexible GnRH antagonist protocol.
Study Overview
Status
Conditions
Detailed Description
All women receive 21 days of an oral contraceptive. A MF protocol will be used for ovarian stimulation in 90 patients. Three days after the last pill, a GnRH-agonist buserelin (Suprefact, Aventis Pharma, Frankfurt, Germany) 50 µg SC twice daily will be initiated and two days after that, recombinant FSH (Gonal-F, Serono, Aubonne, Switzerland) or hMG (Merional, IBSA, Lugano, Switzerland) 300-450 IU/day will be administered. Ninetyty patients will be assigned to an A/L protocol. After oral contraceptive withdrawal bleeding on day 3 of cycle, recombinant FSH or hMG 300-450 IU/day will be initiated and letrozole (Femara, Novartis, East Hanover, NJ) 5 mg/day will be administered for 5 days. When the dominant follicle reached 14 mm in mean diameter, ganirelix acetate (Antagon, Organon, West Orange, NJ) 0.25 mg SC daily will be started.
Patients weill be monitored by serial vaginal ultrasonography and measurement of serum E2 level. When at least two follicles with a mean diameter of 18 mm will be achieved hCG (Pregnyl, Organon, Oss, the Netherlands) 10000 IU will be administered. Cycle cancellation will be considered when fewer than two follicles with normal growth pattern weill be noted.
Oocyte retrieval will be performed 34-36 hours after hCG administration. Conventional IVF or intracytoplasmic sperm injection (ICSI) will be performed as appropriate. Embryos with 4-6 equally sized blastomers on day 2 with ≤ 20% fragmentation and no multinucleation will be considered top quality embryos. Embryos with 2-6 equally or unequally blastomers with ≤20% fragmentation and no multinucleation will be considered good quality embryos. Embryos will be transferred on day 2 or 3 under ultrasound guidance, with a C.C.D. embryo transfer catheter ( Laboratoire C.C.D., Paris, France). Luteal support with progesterone in oil (Progesterone, Aburaihan Co., Tehran, Iran) 100 mg daily IM will be started on the day of oocyte retrieval.
Serum β-hCG level will be measured 14 days after embryo transfer and a transvaginal ultrasonography will be performed 3 weeks after positive β-hCG for documentation of gestational sac and fetal heart activity. Clinical pregnancy will be considered as the presence of a gestational sac with fetal heart activity.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Yazd, Iran, Islamic Republic of, 8916877391
- Research and clinical center for infertility
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- at least one previous failed IVF cycle in which three or fewer follicles with a mean diameter of 16 mm were achieved, and/or
- serum E2 level measured on the day of hCG administration was ≤500 pg/ml
Exclusion Criteria:
- day 3 serum FSH level ≥12 mIU/mL
- there is no age limit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
|
letrozole 5mg/day from day 3 to day 7 of menstrual cycle
Other Names:
oral contraceptive, first 21 days
Other Names:
recombinant FSH or hMG 300-450 IU/day
Other Names:
GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
Other Names:
|
Active Comparator: 2
MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
|
oral contraceptive, first 21 days
Other Names:
recombinant FSH or hMG 300-450 IU/day
Other Names:
50 µg SC twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
pregnancy rate
Time Frame: 5 weeks
|
5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
stimulation outcomes
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: homa oskouian, M.D., Research and clinical center for infertility
- Principal Investigator: robab davar, MD, Research and clinical center for infertility
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Reproductive Control Agents
- Contraceptive Agents, Female
- Fertility Agents, Female
- Fertility Agents
- Letrozole
- Contraceptive Agents
- Contraceptives, Oral
- Ganirelix
- Buserelin
Other Study ID Numbers
- 1969yazdRCCI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ovarian Stimulation
-
Menoufia UniversityRecruitingOvarian StimulationEgypt
-
Minia UniversityUnknownOvarian Stimulation
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Yazd Research & Clinical Center for InfertilityCompletedOvarian StimulationIran, Islamic Republic of
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
Ferring PharmaceuticalsTerminatedControlled Ovarian StimulationDenmark
-
Instituto BernabeuCompleted
-
Meir Medical CenterCompletedOvarian StimulationIsrael
-
Ferring PharmaceuticalsActive, not recruitingControlled Ovarian StimulationDenmark, Norway, Sweden, Switzerland
-
Ferring PharmaceuticalsCompleted
Clinical Trials on letrozole
-
Helsinki University Central HospitalFoundation for Paediatric Research, FinlandCompletedConstitutional Delay of Growth and PubertyFinland
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
Institut du Cancer de Montpellier - Val d'AurelleNovartisCompleted
-
University of Alabama at BirminghamGenentech, Inc.; Breast Cancer Research FoundationCompletedBreast Cancer | Breast Neoplasm | Cancer of the BreastUnited States
-
Fudan UniversityRecruitingEndometrial CancerChina
-
IVI MadridActive, not recruitingLuteinised Follicular CystSpain
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedBreast Neoplasms
-
Novartis PharmaceuticalsCompletedBreast NeoplasmUnited States, Germany, Spain, United Kingdom, France, Austria, Russian Federation, Italy, Canada, Belgium
-
Assiut UniversityRecruitingInfertility, FemaleEgypt
-
Genor Biopharma Co., Ltd.Recruiting